Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484817 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL64736 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Bromide SCHEMBL1306907 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3406274 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3558297 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL34474654 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3569953 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL13770770 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL11841948 | 0.86 | NOS1 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL255044 | 0.85 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-2966067-B1 | OXAZEPINES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9695192-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695192-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2016015598-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-04 | — | — | WO | disclosed |
| EP-2966067-A1 | OXAZEPINES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150239904-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239904-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2726469-B1 | OXAZEPINES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8962610-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962610-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130005706-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005706-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-03 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | SLC6A2 314/4885SLC6A4 352/4885SLC6A3 282/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | SLC6A2 2553/4885SLC6A4 4367/4885SLC6A3 3772/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | SLC6A2 4743/4885SLC6A4 2681/4885SLC6A3 3786/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | SLC6A2 314/4885SLC6A4 352/4885SLC6A3 282/4885 |
| US-20130005706-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | SLC6A2 635/4885SLC6A4 380/4885SLC6A3 459/4885 |
| US-20150239904-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | SLC6A2 635/4885SLC6A4 380/4885SLC6A3 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.